{"References": [{"title": "Targeting protein tyrosine phosphatases for anticancer drug discovery", "authors": "Zhong-Yin Zhang", "journal": "Molecular Cancer Therapeutics", "year": "2017", "volumes": "16", "first page": "1247", "last page": "1257", "DOI": "10.1158/1535-7163.MCT-16-0782"}, {"title": "Dual-specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling", "authors": "Christopher J. Caunt, Stephen M. Keyse", "journal": "FEBS Journal", "year": "2013", "volumes": "280", "first page": "489", "last page": "504", "DOI": "10.1111/j.1742-4658.2012.08716.x"}, {"title": "Small-molecule inhibitors of protein tyrosine phosphatases", "authors": "Rebecca J. Combs, John S. Lazo, Elizabeth R. Sharlow", "journal": "Expert Opinion on Therapeutic Patents", "year": "2018", "volumes": "28", "first page": "431", "last page": "445", "DOI": "10.1080/13543776.2018.1459568"}, {"title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases", "authors": "Ying Chen, Yong Xu, Qiang Bao, Yan Xing, Zheng Li, Zhuolei Lin, Jia-Bao Stock, Philip D. Jeffrey, Yigong Shi", "journal": "Nature", "year": "2016", "volumes": "535", "first page": "148", "last page": "152", "DOI": "10.1038/nature18621"}, {"title": "Targeting the MAPK signaling pathway in cancer: Promising preclinical activity with the novel selective ERK1/2 inhibitor BVD-523 (ulixertinib)", "authors": "Jeffrey A. Moschos, Daniel O. Sullivan, William Hwu, Ravi K. Ramanathan, Anthony W. Tolcher, Patricia C. Lorusso, Jeffrey R. Infante, Manish R. Patel, Carrie B. Lee, Johanna Bendell, Scott Shanks, Christy Lam, Rachel Doubek, Kimberly Gallo, James Gallo, Gideon Bollag, Yulei Wang, Julie Wolter, Kevin S. Scher, Adeboye O. Osunkoya, Taofeek K. Owonikoko, Suresh S. Ramalingam", "journal": "Molecular Cancer Therapeutics", "year": "2018", "volumes": "17", "first page": "1355", "last page": "1364", "DOI": "10.1158/1535-7163.MCT-17-1119"}, {"title": "Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses", "authors": "Andrew M. Kidger, Stephen M. Keyse", "journal": "Nature Reviews Drug Discovery", "year": "2016", "volumes": "15", "first page": "288", "last page": "306", "DOI": "10.1038/nrd.2015.41"}, {"title": "Allosteric inhibition of SHP2: Identification of a potent, selective, and orally efficacious phosphatase inhibitor", "authors": "Matthew W. Martin, Jennifer Newcomb, Jian Jeffrey Nunes, Daniel C. McGowan, David L. Armistead, Cynthia Boucher, Joshua L. Buchanan, Wendy Buckner, Lixia Chai, Daniel Elbaum, Lesley A. Epstein, Thomas Faust, Stephen Flynn, Paul Gallant, Ami Gore, Yongjin Gu, Frederick Hsieh, Xiang Huang, Joseph H. Lee, Danielle Metz, Stephanos Middleton, Daniel Mohn, Kristin Morgenstern, Michael J. Morrison, Paula M. Novak, Antonio Oliveira, David Powers, Patricia Rose, Scott Schneider, Shenghua Sell, Yun Tao, Andrew P. Combs, Neil T. Leister, Michael D. Rupar, Nicholas A. Schauer, Chao Zhang, Alison D. Roberts", "journal": "Journal of Medicinal Chemistry", "year": "2019", "volumes": "62", "first page": "1793", "last page": "1805", "DOI": "10.1021/acs.jmedchem.8b01621"}, {"title": "Targeting the dual-specificity phosphatases: critical regulators of MAP kinase signalling", "authors": "Jeffrey M. Dickinson, Stephen M. Keyse", "journal": "Chemical Biology & Drug Design", "year": "2006", "volumes": "68", "first page": "3", "last page": "13", "DOI": "10.1111/j.1747-0285.2006.00376.x"}, {"title": "Small molecule inhibitors of protein tyrosine phosphatases", "authors": "Zhong-Yin Zhang", "journal": "Drug Discovery Today", "year": "2017", "volumes": "22", "first page": "1789", "last page": "1794", "DOI": "10.1016/j.drudis.2017.08.001"}, {"title": "Allosteric inhibition of SHP2 phosphatase", "authors": "Xinglu Chen, Yong Xu, Qiang Bao, Yan Xing, Zheng Li, Zhuolei Lin, Jia-Bao Stock, Philip D. Jeffrey, Yigong Shi", "journal": "Nature Chemical Biology", "year": "2016", "volumes": "12", "first page": "797", "last page": "805", "DOI": "10.1038/nchembio.2146"}]}